Lu Da-Yong, Wu Hong-Ying, Yarla Nagendra Sastry, Xu Bin, Ding Jian, Lu Ting-Ren
School of Life Sciences, Shanghai University, Shanghai 200444, China.
College of Science, Shanghai University, Shanghai 200444, China.
Infect Disord Drug Targets. 2018;18(1):15-22. doi: 10.2174/1871526517666170505122800.
AIDS (acquired immune deficient syndrome) is a deadly human viral infectious disease caused by HIV (human immune-deficient virus) infection. Almost every AIDS patient losses his/her life before mid 1990s. AIDS was once the 1st disease killer in US (1993). After one decade hard work, antiviral drug cocktails-high active anti-retroviral therapy (HAART) have been invented for almost all HIV infection treatments. Due to the invention of HAART, 80-90% HIV/AIDS patients still effectively response to HAART for deadly AIDS episode controls and life saving. Yet, this type of HIV therapeutics is incurable. HIV/AIDS patients need to take HAART medications regularly and even life-long. To counteract this therapeutic drawback, more revolutionary efforts (different angles of therapeutic modes/attempts) are urgently needed. In this article, the major progresses and drawbacks of HIV/AIDS chemotherapy (HAART) to HIV/AIDS patients have been discussed. Future trends (updating pathogenesis study, next generations of drug developments, new drug target discovery, different scientific disciplinary and so on) are highlighted.
艾滋病(获得性免疫缺陷综合征)是一种由人类免疫缺陷病毒(HIV)感染引起的致命性人类病毒性传染病。几乎每一位艾滋病患者在20世纪90年代中期之前都会死亡。艾滋病曾是美国(1993年)的头号疾病杀手。经过十年的艰苦努力,已经发明了用于几乎所有HIV感染治疗的抗病毒药物鸡尾酒疗法——高效抗逆转录病毒疗法(HAART)。由于HAART的发明,80%至90%的HIV/AIDS患者对HAART仍有有效反应,可控制致命的艾滋病发作并挽救生命。然而,这种类型的HIV治疗方法无法治愈。HIV/AIDS患者需要定期甚至终身服用HAART药物。为了克服这一治疗缺陷,迫切需要更多革命性的努力(不同角度的治疗模式/尝试)。在本文中,讨论了HIV/AIDS化疗(HAART)对HIV/AIDS患者的主要进展和缺点。突出了未来的趋势(更新发病机制研究、新一代药物开发、新药物靶点发现以及不同的科学学科等)。